^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    GPC3 positive

    i
    Entrez ID:
    2719
    Related biomarkers:
    Expression
    Apply
    Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (NCT02905188)
    Phase 1
    Baylor College of Medicine
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    03/28/2019
    Primary completion :
    11/17/2021
    Completion :
    01/06/2023
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous
    Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (NCT05450562)
    Phase 1/2
    Sanofi
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    09/20/2022
    Primary completion :
    12/12/2030
    Completion :
    12/12/2030
    ALK • GPC3
    |
    GPC3 expression • GPC3 positive
    |
    Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • SAR444200
    A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (ATHENA) (NCT06084884)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    11/27/2023
    Primary completion :
    12/13/2027
    Completion :
    12/13/2027
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide
    Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (NCT04715191)
    Phase 1
    Baylor College of Medicine
    Not yet recruiting
    Last update posted :
    05/06/2024
    Initiation :
    07/03/2024
    Primary completion :
    08/01/2026
    Completion :
    07/03/2041
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous
    T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA3) (NCT04864054)
    Phase 2
    Eureka Therapeutics Inc.
    Recruiting
    Last update posted :
    05/06/2024
    Initiation :
    03/11/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    GPC3
    |
    GPC3 expression • GPC3 positive
    |
    cyclophosphamide • Stivarga (regorafenib) • ECT204
    B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (NCT05070156)
    Phase 1
    Tongji University
    Active, not recruiting
    Last update posted :
    12/15/2023
    Initiation :
    10/29/2021
    Primary completion :
    08/31/2024
    Completion :
    09/30/2024
    GPC3
    |
    GPC3 positive
    |
    B010-A
    NWRD06 DNA Plasmid for HCC After Radical Resection (NCT06088459)
    Phase 1
    Newish Technology (Beijing) Co., Ltd.
    Recruiting
    Last update posted :
    10/18/2023
    Initiation :
    11/01/2023
    Primary completion :
    12/01/2024
    Completion :
    06/01/2025
    GPC3
    |
    GPC3 positive
    Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (NCT05103631)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    08/23/2023
    Initiation :
    06/17/2021
    Primary completion :
    01/01/2025
    Completion :
    12/01/2039
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • AGAR T cells • cyclophosphamide intravenous
    Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (NCT04377932)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    07/07/2023
    Initiation :
    12/08/2021
    Primary completion :
    02/01/2025
    Completion :
    02/01/2040
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • AGAR T cells • GLYCAR T cells • cyclophosphamide intravenous
    Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (NCT02932956)
    Phase 1
    Baylor College of Medicine
    Active, not recruiting
    Last update posted :
    06/06/2023
    Initiation :
    12/17/2018
    Primary completion :
    09/27/2021
    Completion :
    02/01/2037
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GAP T cells • cyclophosphamide intravenous
    GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression (ZZCART-003) (NCT03198546)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    02/28/2023
    Initiation :
    07/01/2017
    Primary completion :
    08/01/2025
    Completion :
    08/01/2029
    GPC3
    |
    GPC3 expression • GPC3 positive
    |
    TGFβ targeting CAR-T cells
    Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma (NCT05620706)
    Phase N/A
    Shenzhen University General Hospital
    Recruiting
    Last update posted :
    11/22/2022
    Initiation :
    11/01/2022
    Primary completion :
    10/31/2025
    Completion :
    10/31/2028
    GPC3
    |
    GPC3 positive
    A Study of CM350 in Patients With Advanced Solid Tumors (NCT05263960)
    Phase 1/2
    Keymed Biosciences Co.Ltd
    Recruiting
    Last update posted :
    06/09/2022
    Initiation :
    04/21/2022
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    GPC3
    |
    GPC3 positive
    |
    CM350
    Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma (NCT05344664)
    Phase 1
    Peking University
    Not yet recruiting
    Last update posted :
    04/25/2022
    Initiation :
    04/14/2022
    Primary completion :
    10/14/2024
    Completion :
    02/01/2025
    GPC3
    |
    GPC3 positive
    |
    GPC3-CAR-T cells
    GPC3-CAR-T Cells for the Hepatocellular Carcinoma (NCT04506983)
    Phase 1
    Beijing Tsinghua Chang Gung Hospital
    Suspended
    Last update posted :
    02/14/2022
    Initiation :
    06/10/2022
    Primary completion :
    06/10/2023
    Completion :
    10/10/2023
    GPC3
    |
    GPC3 positive
    |
    GPC3-CAR-T Cells
    Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors (NCT03302403)
    Phase N/A
    Kang YU
    Active, not recruiting
    Last update posted :
    10/08/2020
    Initiation :
    12/29/2017
    Primary completion :
    12/12/2020
    Completion :
    12/12/2023
    CLDN18 • GPC3
    |
    CD19 positive • GPC3 positive
    |
    cyclophosphamide • fludarabine IV • satricabtagene autoleucel (CT041) • CT011 • CT0180 • CT032 • cyclophosphamide intravenous • zevorcabtagene autoleucel (CT053)
    T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) (NCT04093648)
    Phase 1
    Baylor College of Medicine
    Withdrawn
    Last update posted :
    05/20/2020
    Initiation :
    01/01/2020
    Primary completion :
    02/01/2023
    Completion :
    01/01/2038
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous
    CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma (NCT03146234)
    Phase N/A
    RenJi Hospital
    Completed
    Last update posted :
    08/28/2019
    Initiation :
    03/17/2017
    Primary completion :
    10/18/2018
    Completion :
    10/18/2018
    GPC3
    |
    GPC3 expression • GPC3 positive
    |
    cyclophosphamide • fludarabine IV • CT0180
    Anti-GPC3 CAR T for Treating Patients With Advanced HCC (NCT02395250)
    Phase 1
    RenJi Hospital
    Completed
    Last update posted :
    08/28/2019
    Initiation :
    03/01/2015
    Primary completion :
    06/01/2016
    Completion :
    11/01/2018
    GPC3
    |
    GPC3 expression • GPC3 positive
    A Study of ERY974 in Patient With Advanced Solid Tumors (NCT02748837)
    Phase 1
    Chugai Pharmaceutical
    Completed
    Last update posted :
    08/22/2019
    Initiation :
    08/01/2016
    Primary completion :
    08/01/2019
    Completion :
    08/01/2019
    GPC3
    |
    GPC3 positive
    |
    ERY974
    Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) (NCT03084380)
    Phase 1/2
    Xinqiao Hospital of Chongqing
    Unknown status
    Last update posted :
    03/20/2017
    Initiation :
    06/01/2017
    Primary completion :
    05/31/2019
    Completion :
    05/31/2020
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV
    Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma (NCT02876978)
    Phase 1
    CARsgen Therapeutics Co., Ltd.
    Unknown status
    Last update posted :
    08/24/2016
    Initiation :
    03/01/2016
    Primary completion :
    10/01/2017
    Completion :
    04/01/2019
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • CT0180 • cyclophosphamide intravenous